Jiangsu Vcare key facts
as of Oct 2026- Developer of innovative drugs designed to treat cardiovascular and cerebrovascular, tumors, endocrine, and other areas of chronic diseases.
- Jiangsu Vcare is valued at approximately $162.4M as of Oct 2026 (last reported valuation).
- It has raised $225.4M; the latest was Later Stage VC ($27.3M) in Jan 2025.
- Notable investors include Zijin Hi-Tech Venture Capital, CMG SDIC Fund, Nanjing Innovation Capital Group, Hubei Yangtze River Industrial Investment Group, China Life Private Equity — 17 tracked in total.
- Status: Privately Held (backing).
Jiangsu Vcare's last reported valuation, Feb 2021. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch Jiangsu Vcare: the Monday email on marks, rounds and moves
Jiangsu Vcare funding rounds
No funding rounds for Jiangsu Vcare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Jiangsu Vcare
17+Membership and data by Private Market View
Jiangsu Vcare valuation
Jiangsu Vcare's last reported valuation was $162 million in Feb 2021. No priced round, secondary trade or fund mark has surfaced since.
Jiangsu Vcare investors
17 investors are on record for Jiangsu Vcare, including Zijin Hi-Tech Venture Capital, CMG SDIC Fund, Nanjing Innovation Capital Group and Hubei Yangtze River Industrial Investment Group.
About Jiangsu Vcare
Developer of innovative drugs designed to treat cardiovascular and cerebrovascular, tumors, endocrine, and other areas of chronic diseases. The company's drugs focus on chemical molecular structure optimization and differentiated solutions to clinical needs in the form of generic and innovative drugs and featured pharmaceutical intermediates, providing research and development services for the whole industry chain of chemical drugs.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2010
- Employees
- 900
- Website
- vcarepharmatech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.